Skip to main content
SpringerLink
Log in

Predictive factors for neurocognitive function and Quality of Life after surgical treatment for Cushing’s disease and acromegaly

  • Electronic Contents
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Cushing’s disease (CD) and acromegaly (AC) are associated with impairment in quality of life (QoL) and neurocognition that can persist after successful treatment. Aim: To investigate the influence of current disease status (remission vs no remission) on neurocognitive function and QoL in treated CD and AC patients and to determine predictive factors (e.g. demographic, clinical, neurosurgical, endocrinological) for post-operative neurocognition and QoL. Subjects and methods: Twenty-four CD and 37 AC patients underwent neuropsychological testing 1 to 10 yr following surgical therapy. Additionally, QoL was assessed. An overnight 2-mg dexamethasone suppression test in CD and IGF-I and GH levels in AC patients were assessed to determine current disease status. The results were compared with 28 sex-, education- and age-matched healthy controls (HC). Results: Impaired QoL was more pronounced than neurocognitive decrease in both pathologies compared to HC. This finding was independent of the current status of disease. In AC, persistent comorbidities were associated with impaired QoL (p<0.05). Older age at operation in AC patients was a significant predictor for adverse effects on psychomotor speed and attentional functions (p<0.05). In CD persistent hypocortisolism, not hypercortisolism, had adverse effects on neurocognition (p<0.01). Conclusions: The current status of disease plays a subordinate role in postoperative outcome concerning QoL and neurocognition in either pathology. A possible explanation might be the considerably improved endocrinopathy after treatment compared to untreated patients, even if no cure is achieved. The lasting impairments might be explained by irreversible changes that have occurred during the active phase of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yanovski JA, Cutler GB Jr. Glucocorticoid action and the clinical feature of Cushing’s syndrome. Endocrinol Metab Clin North Am 1994, 23: 487–509.

    PubMed  Google Scholar 

  2. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing’s syndrome after correction or hypercortisolism. J Clin Endocrinol Metab 1997, 82: 912–9.

    PubMed  Google Scholar 

  3. van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 2005, 90: 279–86.

    Article  Google Scholar 

  4. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007, 92: 1743–7.

    Article  PubMed  Google Scholar 

  5. Furman K, Ezzat S. Psychological features of acromegaly. Psychother Psychosom 1998, 67: 147–53.

    Article  PubMed  Google Scholar 

  6. Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary 2002, 5: 7–9.

    Article  Google Scholar 

  7. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004, 89: 5369–76.

    Article  PubMed  Google Scholar 

  8. Guinan EM, Lowy C, Stanhope N, Lewis PD, Kopelman MD. Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatr 1998, 65: 870–6.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Heald A, Parr C, Gibson C, O’driscoll K, Fowler H. A cross-sectional study to investigate long-term cognitive function in people with treated pituitary Cushing’s disease. Exp Clin Endocrinol Diabetes 2006, 114: 490–7.

    Article  PubMed  Google Scholar 

  10. Hook JN, Giordani B, Schteingart DE, et al. Patterns of cognitive change over time and relationship to age following successful treatment of Cushing’s disease. J Int Neuropsychol Soc 2007, 13: 21–9.

    Article  PubMed  Google Scholar 

  11. Martignoni E, Costa A, Sinforiani E, et al. The brain as a target for adrenalcortical steroids: Cognitive implications. Psychoneuroendocrinology 1992, 17: 343–54.

    Article  PubMed  Google Scholar 

  12. Mauri M, Sinforiani E, Bono G, et al. Memory impairment in Cushing’s disease. Acta Neurol Scand 1993, 87: 52–5.

    Article  PubMed  Google Scholar 

  13. Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing’s syndrome and depression — a prospective study of 26 patients. Br J Psychiatry 1983, 142: 16–9.

    Article  PubMed  Google Scholar 

  14. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol 1996, 45: 715–20.

    Article  Google Scholar 

  15. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006, 83: 224–9.

    Article  PubMed  Google Scholar 

  16. Paisley AN, Rowles SV, Roberts ME, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol 2007, 67: 358–62.

    Article  Google Scholar 

  17. Sardella C, Lombardi M, Rossi G, et al. Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest 2010, 33: 20–5.

    Article  PubMed  Google Scholar 

  18. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire. J Clin Endocrinol Metab 2005, 90: 3337–41.

    Article  PubMed  Google Scholar 

  19. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 2006, 155: 831–7.

    Article  PubMed  Google Scholar 

  20. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93: 2454–62.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509–17.

    Article  PubMed  Google Scholar 

  22. Brickenkamp R. d2 Aufmerksamkeits-Belastungs-Test (9th ed). Göttingen: Hogrefe, 2002.

    Google Scholar 

  23. Wechsler D. Wechsler Adult Intelligence Scale (3rd ed). San Antonio: The Psychological Corporation 1997.

    Google Scholar 

  24. Liepmann D, Beauducel A, Brocke B, Amthauer R. Intelligenz-Struktur-Test 2000 R (2nd ed). Göttingen: Hogrefe, 2007.

    Google Scholar 

  25. Oswald W, Roth E. Der Zahlenverbindungstest (2nd ed). Göttingen: Hogrefe, 1987.

    Google Scholar 

  26. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med Care 1992, 30: 473–83.

    Article  PubMed  Google Scholar 

  27. Derogatis LR. SCL-90-R: administration, scoring and procedures manual. Towson: Clinical Psychiatric Association, 1983.

    Google Scholar 

  28. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002, 57: 251–8.

    Article  Google Scholar 

  29. Badia X, Webb SM, Prieto L, Lara N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2004, 2: 13.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Grattan-Smith PJ, Morris JG, Shores EA, Batchelor J, Sparks RS. Neuropsychological abnormalities in patients with pituitary tumours. Acta Neurol Scand 1992, 86: 626–31.

    Article  PubMed  Google Scholar 

  31. Peace KA, Orme SM, Thompson AR, Padayatty S, Ellis AW, Belchetz PE. Cognitive dysfunction in patients treated for pituitary tumours. J Clin Exp Neuropsychol 1997, 19: 1–6.

    Article  PubMed  Google Scholar 

  32. Starkman MN, Giordani B, Berent S, Schork MA, Schteingart DE. Elevated Cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosom Med 2001, 63: 985–93.

    PubMed  Google Scholar 

  33. Bourdeau I, Bard C, Noël B, et al. Loss of brain volume in endogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002, 87: 1949–54.

    PubMed  Google Scholar 

  34. Page RC, Hammersley MS, Burke CW, Wass JA. An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 1997, 46: 401–6.

    Article  Google Scholar 

  35. Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary 2003, 6: 81–7.

    Article  PubMed  Google Scholar 

  36. Heald AH, Ghosh S, Bray S, Gibson C, et al. Long-term negative impact of quality of life in patients with successfully treated Cushing’s disease. Clin Endocrinol 2004, 61: 458–65.

    Article  Google Scholar 

  37. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 2006, 91: 447–53.

    Article  PubMed  Google Scholar 

  38. Dekkers OM, Biermasz NR, Smit JW, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol 2006, 154: 483–9.

    Article  PubMed  Google Scholar 

  39. Luria AR. The neuropsychology of memory. New York: John Wiley, 1976.

    Google Scholar 

  40. Lishman WA. Organic psychiatry: the psychological consequences of cerebral disorder. 2nd ed. Oxford: Blackwell 1987.

    Google Scholar 

  41. Freedman L, McFadden L. Diencephalic amnesia secondary to craniopharyngioma. J Int Neuropsychol Soc 1995, 1: 170.

    Google Scholar 

  42. Meyers CA. Neurobehavioral functioning of adults with pituitary disease. Psychother Psychosom 1998, 67: 168–72.

    Article  PubMed  Google Scholar 

  43. Whelan TB, Schteingart DE, Starkman MN, Smith A. Neuropsychological deficits in Cushing’s syndrome. J Nerv Ment Dis 1980, 168: 753–7.

    Article  PubMed  Google Scholar 

  44. Starkman MN, Schteingart DE. Neuropsychiatric manifestifications of patients with Cushing’s syndrome. Arch Intern Med 1981, 141: 215–9.

    Article  PubMed  Google Scholar 

  45. Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing’s syndrome: ‘atypical’ or melancholic features. Clin Endocrinol 1995, 43: 433–42.

    Article  Google Scholar 

  46. Peace KA, Orme SM, Padayatty SJ, Godfrey HP, Belchetz PE. Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication. Clin Endocrinol 1998, 49: 391–6.

    Article  Google Scholar 

  47. Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing’s syndrome. Psychoneuroendocrinology 2002, 27: 367–83.

    Article  PubMed  Google Scholar 

  48. Webb SM, Badia X, Barahona MJ, et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 2008, 158: 623–30.

    Article  PubMed  Google Scholar 

  49. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992, 32: 756–65.

    Article  PubMed  Google Scholar 

  50. Simmons NE, Do HM, Lipper, MH, Laws ER Jr. Cerebral atrophy in Cushing’s disease. Surg Neurol 2000, 53: 72–6.

    Article  PubMed  Google Scholar 

  51. Negro PJ, Bertolino A, Rosenstein D, et al. Generalized brain volumetric reductions in Cushing’s disease. Program of the 82nd Annual Meeting of the Endocrine Society, Toronto, p. 466 (abstract)

  52. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88: 5593–602.

    Article  PubMed  Google Scholar 

  53. De Kloet ER, Oitzl MS, Joëls M. Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci 1999, 22: 422–6.

    Article  PubMed  Google Scholar 

  54. Sandi C, Rose SPR. Corticosterone enhances long-term memory in one day-old chicks trained in a weak passive avoidance learning paradigm. Brain Res 1994, 647: 106–12.

    Article  PubMed  Google Scholar 

  55. Oitzl MS, Fluttert M, De Kloet ER. The effect of corticosterone on reactivity to spatial novelty is mediated by central mineralcorticosteroid receptors. Eur J Neurosci 1994, 6: 1072–9.

    Article  PubMed  Google Scholar 

  56. Pikkarainen L, Sane T, Reunanen A. The survival and well-being of patients treated for Cushing’s syndrome. J Intern Med 1999, 245: 463–8.

    Article  PubMed  Google Scholar 

  57. Grabner P, Hauer-Jensen M, Jervell J, Flatmark A. Long-term results of treatment of Cushing’s disease by adrenalectomy. Eur J Surg 1991, 157: 461–4.

    PubMed  Google Scholar 

  58. Gotch PM. Cushing’s syndrome from the patient’s perspective. Endocrinol Metab Clin North Am 1994, 23: 607–17.

    PubMed  Google Scholar 

  59. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2: 29–41.

    Article  PubMed  Google Scholar 

  60. Psaras T, Milian M, Hattermann V, Gallwitz B, Freiman T, Honegger J. Aftercare in patients with Cushing’s disease and acromegaly -is there room for improvement? Acta Neurochir (Wien) 2010, 152: 271–9.

    Article  Google Scholar 

  61. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005, 95: 2731–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pituitary Surgery, Department of Neurosurgery, University of Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany

    T. Psaras MD, M. Milian, V. Hattermann, B. E. Will, M. Tatagiba & J. Honegger

Authors
  1. T. Psaras MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Milian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Hattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. E. Will
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Tatagiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Honegger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Psaras MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Psaras, T., Milian, M., Hattermann, V. et al. Predictive factors for neurocognitive function and Quality of Life after surgical treatment for Cushing’s disease and acromegaly. J Endocrinol Invest 34, e168–e177 (2011). https://doi.org/10.3275/7333

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/7333

Key-words

Search

Navigation